Paying for Cures: Ensuring patient access and system sustainability
National Press Club • Washington, DC
February 12, 2019

Hosted by
MIT Center for Biomedical Innovation
NEWDIGS Initiative
Financing and Reimbursement of Cures in the US (FoCUS)

Agenda

Conference Facilitator: Mark Trusheim, MSc, Strategic Director, NEWDIGS

9:30 Welcome
David Goldston, Director, MIT Washington D.C. Office
Krystyn Van Vliet, PhD, Associate Provost and Professor of Materials Science & Engineering & Biological Engineering, MIT
Gigi Hirsch, MD, Executive Director, Center for Biomedical Innovation and Executive Director, NEWDIGS

Part 1: Understanding curative and durable therapies

9:40 Why Are We Here? The Science, Patients and System Readiness for Curative Therapies
This panel will bring together the science, patient and systems perspectives on the advent of durable/curative therapies. Where can the science go from here? How does it impact the hopes, dreams and daily lives of patients and what is the state of operational readiness for the system to deal with this paradigm shift in healthcare.

Moderator
Janet Lynch Lambert, MBA
CEO, Alliance for Regenerative Medicine (ARM)

Panelists
Science
Usman “Oz” Azam, MD
President & CEO, Tmunity Therapeutics

Patients
Marc Boutin, JD
CEO, National Health Council

System
Murray Ross, PhD
Vice President, Kaiser Permanente

Anish Goel, PhD
Beta-Thalassemia patient

10:20 Cell & Gene Therapies Drug Development Pipeline
Colin M. Young, PhD, Director, Drug Development Pipeline Research, MIT FoCUS Project

Part 2: Challenges to Accessibility

10:55 Financial Challenges Imposed by Curative Therapies: Real or Imagined
Panelists will react to the previous panel session on the Science, Patient and Systems dynamics as they relate to the advent of cell and gene therapy rollouts and what they meant to the future of healthcare, as well as predications of the drug development pipeline. Panelists will discuss the many challenges beyond price, presented by the durable/curative therapies from each stakeholder perspective.

Moderator
Steve Usdin
Senior Editor (Washington), Head Policy & Regulation, BioCentury and BioCentury Innovations

Panelists
Patient Advocacy
Tim Brent
Senior Director, Business Development, National Hemophilia Foundation

Public Payer
Darin Gordon
Founding Partner, Speire Healthcare Strategies, (former Director, Tennessee Medicaid program, TennCare)

Government/Regulatory
John O’Brien, PharmD, MPH (invited)
Senior Advisor for Drug Pricing Reform, Health and Human Services

Provider
Joseph Alvarnas, MD
CEO, Equity Healthcare
(Former Executive Director, Health Services & Chief Medical Officer, General Electric)

Self-Insured Employer
Robert Galvin, MD
CEO, Equity Healthcare
(Former Executive Director, Health Services & Chief Medical Officer, General Electric)

National Payer
Patricia Martin, RN, BSN
Director, Specialty Network Development, Anthem, Inc.

THANK YOU to the Paying for Cures Organizing Committee and management team:
Mike Ciarametaro (NPC), Ester Krofah (FasterCures), Francesca Cook (RegenXBio), Danielle Rollman, Gary Surmay (Pfizer), Rob Falb (ARM), Virginia Sweeter, Katie Torrence, Eric Small, Matt Courtney, Eric Norman, Mark Trusheim, and Deborah Young.
12:10  Lunch

12:35  Keynote: Senator Bill Cassidy, MD, U.S. Senator for Louisiana
How medicine is changing, what it means to improved health and why there is a need to create alternative financing mechanisms.

Introduction  Jonathan Gruber, PhD, Ford Professor of Economics, MIT and Director, Health Care Program, National Bureau of Economic Research

1:00  The FoCUS Project: Precision Financing Solutions
Go behind the scenes with this panel on the creation of financing and reimbursement solutions to the myriad of challenges brought by the upfront cost of the durable/curative therapies. Stakeholder representatives will highlight and review the case studies utilized in the development of precision financing ideas.

Moderator  Mark Trusheim, MSc
Strategic Director, NEWDIGS

Panelists
FoCUS Project
Development & Goals
Edmund Pezalla, MD, MPH
CEO Enlightenment
Bio-consulting (former Vice President, National Medical Director, Pharmaceutical Policy and Strategy, Aetna)

Blood Disorders Case study / Performance-based Annuities
Chuck Bucklar
Group Vice President, Commercial Operations, North America, BioMarin Pharmaceutical Inc.

CAR-T Case Study / Milestone-based Rebates
Krishna Komanduri, MD
Kalish Family Chair in Stem Cell Transplantation; Professor of Medicine and Associate Director, Clinical Innovation, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

Ultra-Orphans Case Study / Orphan Reinsurer Benefit Manager
Michael Ciarametaro, MBA
Vice President Research, National Pharmaceutical Council

1:50  Break

Part 3: Clearing The Way for Cures

2:00  Putting Theory into Practice
This panel will describe the pilots FoCUS is designing, including plans for a Massachusetts pilot on performance-based annuities with commercial payers, and milestone-based contracts with public payers.

Moderator  Rena Conti, PhD
Associate Professor, Markets, Public Policy, and Law; Associate Research Director, Biopharma and Public Policy, Institute for Health System Innovation and Policy, Boston University Questrom School of Business

Panelists
Performance-based Annuities with Commercial Payers
Lovenia Chaput
Vice President, Managed Markets & Reimbursement, AveXis

Milestone-based Contracts with Public Payers
John Glasspool
Board Member, DalCor Pharmaceuticals, Senior Advisor, MIT FoCUS Project

Jeff Myers
EVP Strategy and External Relations, CareSource (former president and CEO of Medicaid Health Plans of America (MHPA))

Michael Sherman, MD, MBA, MS
Chief Medical Officer and Senior Vice President, Harvard Pilgrim Health Care

Continued...
2:35 Identifying Opportunities for Enabling Precision Financing
All precision financing solutions, including those proposed by the FoCUS Consortium, will require improvements to existing financial systems. This panel will explore what those challenges are, how they might be overcome and what you can do to aid in this endeavor.

Moderator
Gregory Daniel, PhD, MPH
Deputy Director, Policy, Duke – Robert J. Margolis MD, Center for Health Policy & Clinical Professor, Fuqua School of Business

Panelists
Private Payer, PBM and Medicare
Kim Caldwell, RPh
Principal, Texas Star Healthcare Consulting, LLC (former Division Director, Medicare Drug Benefit Group, CMS; VP of Pharmacy Professional Affairs & Comprehensive Health, Humana Inc.)

Regulatory
Brian Carey
Partner, Foley-Hoag LLP
Stop-Loss/Reinsurance
Mehb Khoja, FSA, MAAA
President, Medical Risk Managers Inc. (MRM)

Patient Advocacy
Peter Saltonstall
President and CEO, National Organization for Rare Disorders (NORD)

3:25 Keynote: Senator Sheldon Whitehouse, JD, U.S. Senator for Rhode Island
The current climate on Capitol Hill around payment reform and opportunities for innovation in pricing arrangements.

Introduction Mark Trusheim, MSc, Strategic Director, NEWDIGS

3:45 Wrap Up – Audience Engagement
Mark Trusheim, MSc, Strategic Director, NEWDIGS

Paying for cures
Challenges, solutions, and what you can do

The growing need
• Durable, potentially curative therapies for genetic disorders and cancer have arrived.
• Short—even single dose—treatment regimens yield lasting health benefits.
• Large single payments will challenge the current reimbursement system.

The challenges
• Policy, regulations, and business operations need to evolve to enable emerging solutions.
• Payers face specific and complex challenges for each of four “Cure Archetypes.”

Precision Financing Strategies
• Milestone-based Contracts
• Performance-based Annuities
• Orphan Reinsurer and Benefit Managers

What you can do
21st century medicine needs a 21st century health-care financing system. To see what you can do to help, go to payingforcures.org